Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
ReutersFeb 18, 2026 1:07 PM
Feb 18 (Reuters) - Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis NOVN.S to develop macrocyclic peptide-based therapies for a cardiovascular program.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.TradingKey
7 hours ago
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
11 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
